• 대한한방소아과학회지
• /
• 제24권1호
• /
• pp.9-35
• /
• 2010

Objectives The purpose of this study is to investigate the effect of SPDJTK(SoPungDoJeokTangKami) and concurrent administration of AJ(Atopy cream, Jawoongo)+SPDJTK on atopic dermatitis-like skin lesions by using in NC/Nga atopic dermatitis mouse induced by BMAC-induced mice. Methods Clinical skin score, hematology and Serum total IgE and IgG1 of NC/Nga atopic dermatitis mice were evaluated. Moreover, the cytokine level, total cell number, Immunohistochemical staining and Histological features of axillary lymph node(ALN), draining lymph node(DLN), peripheral blood mononuclear cells(PBMCs) and dorsal skin tissue were used in NC/Nga mice. Results Orally administrated SPDJTK with concurrent administration of SPDJTK and AJ decreased the clinical skin score, total cell number of WBC, eosinophils in blood, serum total IgE & IgG1, IL-5, IL-13, IFN-$\gamma$. Also, total cell number of ALN and dorsal skin tissue, absolute cell number of CD4+, CD8+, CD3+CD69+, CD3+CCR3+, CCR3+, CD4+CXCR5+ in ALN, absolute cell number of CD3+CCR3+, CCR3+ in DLN, granulocytes in PBMCs, activation cell number of CD3+CD69+, CCR3+, total cell number of CD3+ T cell in dorsal skin tissue were significantly decreased. Furthermore, thickness of epidermis, infiltrated inflammatory immune cell and mast cell in dermis, amount of Eotaxin2 mRNA, CCR3 mRNA in dorsal skin tissue, gene expression of IL-5, IL-13 mRNA in ALN, CD4+ Th cell in dorsal skin tissue and CCR3+ eosinophils in ALN were all significantly decreased. However, total number of DLN, absolute number of CD3e+ T cell and CD19+ B cell, absolute number of CD4+, number of Th cell in DLN and gene expression of foxp3 mRNA were significantly increased significantly. Conclusions Concurrent administration of SPDJTK and AJ on atopic dermatitis in NC/Nga atopic dermatitis mouse was very effective treatment for atopic dermatitis.

• Radiation Oncology Journal
• /
• 제19권1호
• /
• pp.21-26
• /
• 2001

목적 : 보존적수술 후 방사선치료를 받은 유방암 환자를 대상으로 한국인에서의 조기 유방암의 보존적치료의 전반적인 미용적 결과와 유방의 대칭성 및 이에 영향을 미치는 인자들을 분석을 위하여 본 연구를 시행하였다. 대상 및 방법 : 1992년 2월부터 1997년 1월까지 조기유방암으로 보존적수술 후 서울대학교병원 치료방사선과에서 방사선치료를 시행 받은 120명의 환자를 대상으로 하였다. 대상 환자들의 추적관찰 기간은 16개월에서 74개월로 중앙값은 33개월이었다. 유방보존수술은 사분위절제술 및 액와림프절절제술 108례, 종양절제술 및 액와림프절절제술 4례, 종양절제술 2례, 전절제 생검술 4례, 피하유방절제술 및 액와림프절 절제술이 2례였다. 수술 후 방사선치료는 4 MV, 6 MV 또는 10 MV X 선을 이용하여 1 일 1.8 Gy 씩 50.4 Gy를 유방전체에 접선조사야로 조사한 후 원발부위에 7 또는 9 MeV 전자선으로 1일 2 Gy 씩 10 Gy를 추가조사하였으며 21례에서 액와림프절과 쇄골상 림프절을, 9례에서 액와림프절, 쇄골상림프절, 내유림프절을 치료범위에 포함하였다. 항암화학요법은 총 46례에서 시행하였으며, 45례에서 CMF (cyclophosphamide, methotrexate, 5-fluorouracil) 복합요법 6회를, 1례에서 CAF (cyclophosphamide, doxorublcin, 5-fluorouracil) 복합요법 12회를 시행하였다. 전반적인 미용적 결과는 유방의 부종(edema), 수축(retraction), 상승(elevation), 섬유화(fibrosis), 경화(induration) 및 피부변화 등을 고려하여 excellent, good, fair, poor 의 4 단계로 평가하였으며, 유방의 대칭성의 판정을 위하여 symmetry index를 사용하였다 전반적인 미용적 결과의 비교 및 분석을 위하여 polytomous logistic regression 방법을 사용하였고, 유방의 대칭성 평가를 위해 logistic regression 방법을 사용하였다. 결과 : 최종 추적관찰 시 전반적인 미용적 결과는 excellent가 29명$(24\%)$, good 62명$(52\%)$, fair 23명$(19\%)$, poor가 6명$(5\%)$으로 $76\%$의 환자에서 good 이상의 결과를 보였다. 단변량분석 상 종양의 크기가 2 cm 이하인 경우 (p=0.04), 림프절 전이가 없는 경우(p:0.0002), 종양 절제술 또는 전절제생검술을 시행한 경우 (p=0.02), 방사선치료의 범위에 액와림프절이 포함되지 않은 경우(p=0.0005), 항암화학요법을 시행하지 않은 경우(p=0.0001) 더 좋은 미용적 결과를 보였다. 다변량분석 상 종양절제술 또는 전절제생검만을 시행한 경우(p=0.04), 항암화학요법을 시행하지 않은 경우(p=0.0002)에 더 좋은 미용적 결과를 보였다. 유방의 대칭성에 영향을 미치는 요인으로는 단변량분석 상 종양의 크기가 2 cm 이하인 경우(p=0.0007), 림프절 전이가 없는 경우(p=0.005), 항암화학요법을 시행하지 않은 경우 (p=0.001), 방사선치료의 범위에 액와림프절이 포함되지 않은 경우(p=0.02) 에 더 좋은 유방의 대칭성을 보였으며 종양절제술 또는 전절제생검만을 시행한 경우(p=0.09) 대칭성이 높은 경향을 보였다. 다변량분석 상으로는 종양의 크기가 2 cm 이하인 경우(p=0.003), 림프절 전이가 없는 경우(p=0.007) 더 좋은 유방의 대칭성을 보였다. 결론 : 조기유방암에서의 보존적수술 및 방사선치료는 $76\%$의 환자에서 good 이상의 미용적 결과를 보였다. 또한 대상 환자 중 종양의 크기가 작은 경우, 액와림프절 전이가 없는 경우 및 수술의 범위가 작은 경우 미용적 결과가 더 우수함을 확인할 수 있었다.

• Archives of Plastic Surgery
• /
• 제39권2호
• /
• pp.154-157
• /
• 2012

Lymphedema is a common complication after mastectomy in breast cancer patients. Many treatment options are available, but no treatment results in a complete cure. We report a case of lymphedema that occurred after modified radical mastectomy in a breast cancer patient who showed objective improvement after delayed breast reconstruction with an latissimus dorsi myocutaneous flap. A 41-year-old female patient with left breast cancer had undergone modified radical mastectomy with axillary lymph node dissection and postoperative radiotherapy 12 years previously. Four years after surgery, lymphedema developed and increased in aggravation despite conservative treatment. Eight years after the first operation, the patient underwent delayed breast reconstruction using the extended latissimus dorsi myocutaneous flap method. After reconstruction, the patient's lymphedema symptoms showed dramatic improvement by subjective measures including tissue softness and feeling of lightness, and by objective measures of about 7 mL per a week, resulting in near normal ranges of volume. At a postoperative follow-up after 3 years, no recurrence was observed. Delayed breast reconstruction with extended latissimus dorsi myocutaneous flaps may be helpful to patients with lymphedema after mastectomy. This may be a good option for patients who are worried about the possibility of the occurrence or aggravation of secondary lymphedema.

• Radiation Oncology Journal
• /
• 제31권4호
• /
• pp.228-233
• /
• 2013

Purpose: The aim of this study was to evaluate changes in breast tumor bed volume during whole breast irradiation (WBI). Materials and Methods: From September 2011 to November 2012, thirty patients who underwent breast-conserving surgery (BCS) followed by WBI using computed tomography (CT) simulation were enrolled. Simulation CT scans were performed before WBI (CT1) and five weeks after the breast irradiation (CT2). The tumor bed was contoured based on surgical clips, seroma, and postoperative change. We retrospectively analyzed the factors associated with tumor bed volumetric change. Results: The median tumor bed volume on CT1 and CT2 was 29.72 and 28.6 mL, respectively. The tumor bed volume increased in 9 of 30 patients (30%) and decreased in 21 of 30 patients (70%). The median percent change in tumor bed volume between initial and boost CT was -5%. Seroma status (p = 0.010) was a significant factor in tumor bed volume reduction of 5% or greater. However, patient age, body mass index, palpability, T stage, axillary lymph node dissection, and tumor location were not significant factors for tumor bed volumetric change. Conclusion: In this study, volumetric change of tumor bed cavity was frequent. Patients with seroma after BCS had a significant volume reduction of 5% or greater in tumor bed during breast irradiation. Thus, resimulation using CT is indicated for exquisite boost treatment in breast cancer patients with seroma after surgery.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권4호
• /
• pp.1789-1795
• /
• 2016

Background: Breast cancer is the commonest female cancer worldwide and its propensity to metastasize negatively impacts on therapeutic outcome. Several clinicopathological parameters with prognostic/predictive significance have been associated with metastatic suppressor expression levels. The role of metastatic suppressor gene (MSG) KiSS1 in breast cancer remains unclear. Our goal was to investigate the possible clinical significance of KiSS1 breast cancer. Materials and Methods: The study was conducted on 87 histologically proven cases of breast cancer and background normal tiisue. Quantitative reverse transcriptase polymerase chain reaction (qRT PCR) and immunohistochemistry (IHC) were used to investigate KiSS1 at gene and protein levels, respectively, for correlation with several patient characteristics including age, family history, hormonal receptor status, stage, tumor size, nodal involvement and metastatic manifestation and finally with median overall survival (OS). Results: Our study revealed (i) KiSS1 levels were generally elevated in breast cancer vs normal tissue (P < 0.05). (ii) however, a statistically significant lower expression of KiSS1 was observed in metastatic vs non metastatic cases (P = 0.04). (iii) KiSS1 levels strongly correlated with T,N,M category, histological grade and advanced stage (p<0.001) but not other studied parameters. (iv) Lastly, a significant correlation between expression of KiSS1 and median OS was found (P = 0.04). Conclusions: Conclusively, less elevated KiSS1 expression is a negative prognostic factor for OS, advancing tumor stage, axillary lymph node status, metastatic propensity and advancing grade of the breast cancer patient. Patients with negative KiSS1 expression may require a more intensive therapeutic strategy.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권4호
• /
• pp.1559-1563
• /
• 2015

Background: Male breast cancer accounts for less than 1% of all cancers found in men. It usually presents at a later age and stage as compared to female breast cancer. Treatment strategies are extrapolated from the management of female breast cancer. Our study here looked at 18 patients diagnosed with and treated for male breast cancer at The Aga Khan University Hospital in Pakistan. We compared our findings with the existing data from Asian and Western countries. Materials and Methods: A retrospective study was conducted looking at patients with male breast cancer between January 1986 and December 2009. Patient and disease characteristics were analyzed and 5 year overall survival was calculated using Microsoft Excel and SPSS. Results: The average age at diagnosis was 52 years (38-67 years). Twelve (66.7%) patients had axillary lymphadenopathy. Stage II disease was the most common stage at presentation (9 patients, 50%). Infiltrating ductal carcinoma was seen in 16 patients (88.8%). Seven lesions were positive for both estrogen and progesterone receptors. Sixteen patients had surgery in the form of either modified radical mastectomy or radical mastectomy. Radiation was used in 7 patients in an adjuvant setting. The five year overall survival for stage I, II, III and IV disease was 100% vs 78% vs 50% vs 0%( p<0.05). Five year overall survival was 61%. None of the other prognostic factors were statistically significant. Median follow up was 15 months (3-202 months). Conclusions: Male breast cancer may be on a slow rise but is still an uncommon disease. Tumor stage and lymph node status are important prognostic markers. Public awareness and screening may help in detecting the disease at an earlier stage. Prospective trials are needed to improve the management of this disease.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권3호
• /
• pp.873-877
• /
• 2012

MicroRNAs (miRNAs) are short non-coding RNA molecules characterized by their regulatory roles in cancer and gene expression. We analyzed the expression of miR-21, miR-205, and miR-342 in 59 patients with breast cancer. Samples were divided into three different groups according to their immunohistochemistry (IHC) classification: ER- positive and/or PR-positive group ($ER^+$ and/or $PR^+$; group I); HER2-positive group ($HER^{2+}$; group II); and ER/ PR/ HER2- negative ($ER^-$/ $PR^-$/ $HER^{2-}$; group III) as the triple negative group. The expression levels of the 3 miRNAs were analyzed in the tumor samples and the compared with the normal neighboring dissected tumor (NNDT) samples in all three groups. The expression of miR-21 was similar in all three groups. In patients positive for P53 by IHC, positive for axillary lymph node metastasis and higher tumor stages, it appeared to have significantly elevated. However, significant increase was not found among the 18 fibroadenoma samples. Both miR-205 and miR-342 expressions were significantly down regulated in group III. We conclude that miR-21 does not discriminate between different breast cancer groups. In contrast, miR-205 and miR-342 may be used as potential biomarkers for diagnosis of triple negative breast cancer.

• Journal of Genetic Medicine
• /
• 제9권1호
• /
• pp.25-30
• /
• 2012

Among the treatment options for BRCA mutation carriers, risk reducing surgery is the most effective. However, this procedure has been rarely performed in Korea. Interestingly, our case showed double heterozygosity for BRCA1 and BRCA2 mutations. The patient was diagnosed with left renal cancer and left breast cancer at 45-years-of-age, 4 years before risk reducing surgery. The patient received left radical nephrectomy and left partial mastectomy with axillary lymph node dissection. After pretest counseling, the patient underwent genetic testing that identified BRCA1 and BRCA2 mutations. After post-test counseling, the patient decided on intensive surveillance. At 49-years-of-age, the patient was newly diagnosed with contralateral breast cancer. Treatment options were discussed once again. We performed bilateral total mastectomy with immediate reconstruction and prophylactic bilateral salpingo-oophorectomy after multidisciplinary discussion. The patient has been satisfied with the results of surgery. We think this procedure is a recommendable treatment option for BRCA mutation carriers.

• Clinical Pain
• /
• 제20권2호
• /
• pp.99-104
• /
• 2021

Objective: To confirm the safety of Intra-articular (IA) injection on the ipsilateral adhesive capsulitis (AC) after breast cancer surgery. Methods: Between January 2017 and May 2020, we retrospectively studied 29 patients after breast cancer surgery who underwent IA injection in the glenohumeral joint for AC in aseptic procedure. Results: There were no side effects or complications such as lymphedema or cellulitis in the patients. There was a significant improvement in pain score and range of motion (ROM) at the 1st, 3rd, and 6th months visits compared to the baseline (p<0.05). The presence or absence of axillary lymph node dissection and radiation therapy had no significant difference in improvement of ROM. But, in rotator cuff syndrome (RCS) group, there was a significant difference in improvement of shoulder IR in patients without RCS. Conclusion: IA Injection on the ipsilateral AC after breast cancer surgery was safe and even effective to improve pain and shoulder ROM. Ipsilateral IA injection can be a good treatment for breast cancer surgery patients suffering from AC.

• 대한영상의학회지
• /
• 제81권1호
• /
• pp.147-156
• /
• 2020

목적 이 연구의 목적은 유방암으로 수술한 환자에서 림프절 재발을 진단함에 있어 미세침흡인세척액 cytokeratin fragment 21-1 (이하 CYFRA 21-1) 측정의 진단적 가치와 적절한 역치값을 평가하는 것이다. 대상과 방법 64명의 유방암 수술을 받은 환자에서 재발이 의심되는 총 64개의 림프절에 대해 미세침흡인세포검사와 미세침세척액 CYFRA 21-1 검사를 시행하였다. 최종 진단은 fine-needle aspiration 세포검사 및 2년 이상의 추적관찰로 하였다. 재발 림프절과 양성 림프절의 CYFRA 21-1의 농도를 비교하였다. 진단수행도와 역치값은 수신기작동특성곡선을 이용하여 구했다. 결과 비진단적 결과와 상관없이, CYFRA 21-1의 중간 농도는 양성 림프절보다 재발 림프절에서 유의하게 높았다(p < 0.001). 적절한 역치값은 1.6 ng/mL였다. 림프절 재발에 대한 CYFRA 21-1의 민감도, 특이도, 양성예측도, 음성예측도 및 정확도는 각각 90.9%, 100%, 100%, 98.1%, 98.4%였다. 결론 미세침세척액에서 CYFRA 21-1 농도 측정은 역치값을 1.6으로 하였을 때 우수한 진단수 행도를 보여주었다. 이 결과는 미세침세척액 CYFRA 21-1 농도 측정이 유방암 수술 환자에서 액와림프절 재발을 진단하는데 있어 유용함을 보여준다.